Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences, Inc. announced that it has entered into a securities purchase agreement to issue 24,500,000 series E-1 preferred stock and warrants for the gross proceeds of up to $102.9...

Related Keywords

,Second Line Capital ,Aigh Capital Management ,Rosalind Advisors Inc ,Cellectar Biosciences Inc ,Nantahala Capital Management ,Augc Partners ,Capital Management ,Cellectar Biosciences ,Rosalind Advisors ,Markets ,